Skip to main content
Premium Trial:

Request an Annual Quote

Enzo Biochem p16

Enzo Biochem launched its p16 cervical cancer biomarker detection test. The test, the firm said, is the latest addition to its immunohistochemistry pipeline, which includes Ki-67, HER2, and p53. The validated p16 test allows for the detection of tissue abnormalities in cancer, including cervical cancer, and it complements Enzo Biochem's Polyview line of immunohistochemistry detection products, the company said.